ERBB2 and breast carcinoma: For patients with early-stage, hormone-positive, HER2-negative breast cancers, the 21-gene assay (Oncotype DX) provides a recurrence score between 0 and 100 that can be used to estimate the likelihood of breast cancer recurrence and potential benefit of adjuvant chemotherapy.